Bladder cancer: Progress in defining progression in NMIBC

Nature Reviews Urology

Volumn 10, Issue 12, 2013, Pages 684-685

  Gierth, Michael ^a   Burger, Maximilian ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CYSTECTOMY; DISEASE COURSE; HUMAN; LAMINA PROPRIA; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TUMOR INVASION;

DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 84890433619     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.270     Document Type: Article

References (10)

1. Lamm, D. et al. Defining progression in non-muscle invasive bladder cancer (NMIBC): it's time for a new, standard definition. J. Urol. http://dx.doi.org/10.1016/j.juro.2013.07.102.
2. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64, 639-653 (2013).
3. Razzak, M. Bladder cancer: gaps in staging and care identified. Nat. Rev. Urol. 10, 493 (2013).
4. Burger, M. et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 54, 835-843 (2008).
5. van Rhijn, B. W. et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 56, 430-432 (2009).
6. Maclennan, G. T., Kirkali, Z. & Cheng, L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur. Urol. 51, 889-897 (2007).
7. Denzinger, S. et al. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int. J. Urol. 14, 995-999 (2007).
8. Bertz, S. et al. Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology 59, 722-732 (2011).
9. Bertz, S. et al. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2012.05.033.
10. Noon, A. P. & Catto, J. W. Bladder cancer in 2012: challenging current paradigms. Nat. Rev. Urol. 10, 67-68 (2013).